Merrill maintains OSI at buy

OSI Pharmaceuticals, Inc. was maintained at a buy rating by Merrill Lynch analyst Eric Ende after Roche's first-quarter 2006 Tarceva sales of $40 million beat the analyst's estimate of $37.5 million, as well as consensus of about $35 million. Merrill increased 2006 Tarceva estimates outside of the United States to $228 million from $222 million. Shares of the Melville, N.Y., biopharmaceutical company were up 72 cents, or 2.79%, at $26.50 on volume of 1,093,089 shares versus the three-month running average of 1,476,280 shares. (Nasdaq: OSIP)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.